Commonwealth Coat of Arms of Australia

 

PB 14 of 2024

 

National Health Legislation Amendment (Maximum Dispensed Quantities) Instrument 2024
 

National Health Act 1953

 

I, NIKOLAI TSYGANOV, Assistant Secretary, Pricing and PBS Policy Branch, Technology Assessment and Access Division, Department of Health and Aged Care, delegate of the Minister for Health and Aged Care, make this Instrument under sections 84AF, 84AK, 85, 85A, 88 and 101 of the National Health Act 1953.

Dated  28 February 2024

NIKOLAI TSYGANOV

Assistant Secretary

Pricing and PBS Policy Branch

Technology Assessment and Access Division

 

 

Contents

1 Name

2 Commencement

3 Authority

4 Schedules

Schedule 1—Maximum dispensed quantities

National Health (Listing of Pharmaceutical Benefits) Instrument 2012. 2

1 Name

(1)          This instrument is the National Health Legislation Amendment (Maximum Dispensed Quantities) Instrument 2024.

(2)          This instrument may also be cited as PB 14 of 2024.

2 Commencement

(1)          Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.

 

Commencement information

Column 1

Column 2

Column 3

Provisions

Commencement

Date/Details

1. The whole of this instrument

1 March 2024

1 March 2024

Note: This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.

(2)          Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.

3 Authority

This instrument is made under sections 84AF, 84AK, 85, 85A, 88 and 101 of the National Health Act 1953.

4 Schedules

Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.

Schedule 1Maximum dispensed quantities

National Health (Listing of Pharmaceutical Benefits) Instrument 2012

[1]                   Schedule 1, Part 1, entry for Acarbose

substitute:

Acarbose

Tablet 50 mg

Oral

a

Acarbose Mylan

AF

MP NP

 

 

90

5

90

 

 

 

 

 

a

Acarbose Viatris

AL

MP NP

 

 

90

5

90

 

 

 

 

 

a

GLYBOSAY

RW

MP NP

 

 

90

5

90

 

 

 

 

 

a

Acarbose Mylan

AF

MP NP

 

P14238

180

5

90

 

 

 

 

 

a

Acarbose Viatris

AL

MP NP

 

P14238

180

5

90

 

 

 

 

 

a

GLYBOSAY

RW

MP NP

 

P14238

180

5

90

 

 

 

Tablet 100 mg

Oral

a

Acarbose Viatris

AL

MP NP

 

 

90

5

90

 

 

 

 

 

a

GLYBOSAY

RW

MP NP

 

 

90

5

90

 

 

 

 

 

a

Acarbose Viatris

AL

MP NP

 

P14238

180

5

90

 

 

 

 

 

a

GLYBOSAY

RW

MP NP

 

P14238

180

5

90

 

 

[2]                   Schedule 1, Part 1, entry for Alendronic acid with colecalciferol

substitute:

Alendronic acid with colecalciferol

Tablet 70 mg (as alendronate sodium) with 70 micrograms colecalciferol

Oral

 

Fosamax Plus

MQ

MP NP

C6307 C6315 C6320 C15011 C15024 C15035

P6307 P6315 P6320

4

5

4

 

 

 

 

 

 

 

 

MP NP

C6307 C6315 C6320 C15011 C15024 C15035

P15011 P15024 P15035

8

5

4

 

 

 

Tablet 70 mg (as alendronate sodium) with 140 micrograms colecalciferol

Oral

 

Fosamax Plus 70 mg/140 mcg

MQ

MP NP

C6306 C6319 C6325 C14898 C14993 C15032

P6306 P6319 P6325

4

5

4

 

 

 

 

 

 

 

 

MP NP

C6306 C6319 C6325 C14898 C14993 C15032

P14898 P14993 P15032

8

5

4

 

 

[3]                   Schedule 1, Part 1, entry for Alogliptin

substitute:

Alogliptin

Tablet 6.25 mg (as benzoate)

Oral

 

Nesina

TK

MP NP

C4349 C14862

P4349

28

5

28

 

 

 

 

 

 

 

 

MP NP

C4349 C14862

P14862

56

5

28

 

 

 

Tablet 12.5 mg (as benzoate)

Oral

 

Nesina

TK

MP NP

C4349 C14862

P4349

28

5

28

 

 

 

 

 

 

 

 

MP NP

C4349 C14862

P14862

56

5

28

 

 

 

Tablet 25 mg (as benzoate)

Oral

 

Nesina

TK

MP NP

C4349 C14862

P4349

28

5

28

 

 

 

 

 

 

 

 

MP NP

C4349 C14862

P14862

56

5

28

 

 

[4]                   Schedule 1, Part 1, entry for Alogliptin with metformin

substitute:

Alogliptin with metformin

Tablet containing 12.5 mg alogliptin (as benzoate) with 1 g metformin hydrochloride

Oral

 

Nesina Met 12.5/1000

TK

MP NP

C4423 C4427 C14876

P4423 P4427

56

5

56

 

 

 

 

 

 

 

 

MP NP

C4423 C4427 C14876

P14876

112

5

56

 

 

 

Tablet containing 12.5 mg alogliptin (as benzoate) with 500 mg metformin hydrochloride

Oral

 

Nesina Met 12.5/500

TK

MP NP

C4423 C4427 C14876

P4423 P4427

56

5

56

 

 

 

 

 

 

 

 

MP NP

C4423 C4427 C14876

P14876

112

5

56

 

 

 

Tablet containing 12.5 mg alogliptin (as benzoate) with 850 mg metformin hydrochloride

Oral

 

Nesina Met 12.5/850

TK

MP NP

C4423 C4427 C14876

P4423 P4427

56

5

56

 

 

 

 

 

 

 

 

MP NP

C4423 C4427 C14876

P14876

112

5

56

 

 

[5]                   Schedule 1, Part 1, entry for Amlodipine with atorvastatin in the form Tablet 10 mg amlodipine (as besilate) with 80 mg atorvastatin (as calcium)

substitute:

 

Tablet 10 mg amlodipine (as besilate) with 80 mg atorvastatin (as calcium)

Oral

a

Cadivast 10/80

AF

MP NP

 

 

30

5

30

 

 

 

 

 

a

Caduet 10/80

AS

MP NP

 

 

30

5

30

 

 

 

 

 

a

Cadivast 10/80

AF

MP NP

 

P14238

60

5

30

 

 

 

 

 

a

Caduet 10/80

AS

MP NP

 

P14238

60

5

30

 

 

[6]                   Schedule 1, Part 1, entry for Anastrozole

substitute:

Anastrozole

Tablet 1 mg

Oral

a

Anastrozole GH

GQ

MP NP

C5464 C14943

P5464

30

5

30

 

 

 

 

 

a

Anastrozole Sandoz

SZ

MP NP

C5464 C14943

P5464

30

5

30

 

 

 

 

 

a

APO-Anastrozole

TX

MP NP

C5464 C14943

P5464

30

5

30

 

 

 

 

 

a

Arianna 1

AF

MP NP

C5464 C14943

P5464

30

5

30

 

 

 

 

 

a

Arimidex

AP

MP NP

C5464 C14943

P5464

30

5

30

 

 

 

 

 

a

Anastrozole GH

GQ

MP NP

C5464 C14943

P14943

60

5

30

 

 

 

 

 

a

Anastrozole Sandoz

SZ

MP NP

C5464 C14943

P14943

60

5

30

 

 

 

 

 

a

APO-Anastrozole

TX

MP NP

C5464 C14943

P14943

60

5

30

 

 

 

 

 

a

Arianna 1

AF

MP NP

C5464 C14943

P14943

60

5

30

 

 

 

 

 

a

Arimidex

AP

MP NP

C5464 C14943

P14943

60

5

30

 

 

[7]                   Schedule 1, Part 1, entry for Bromocriptine

substitute:

Bromocriptine

Tablet 2.5 mg (as mesilate)

Oral

 

Parlodel

SZ

MP

C5172 C6706 C6707 C6717 C6718 C6719 C6787 C14914 C14981 C15017 C15028 C15043 C15044

P5172

30

0

30

 

 

 

 

 

 

 

 

NP

C5172

 

30

0

30

 

 

 

 

 

 

 

 

MP

C5172 C6706 C6707 C6717 C6718 C6719 C6787 C14914 C14981 C15017 C15028 C15043 C15044

P6706 P6707 P6717 P6718 P6719 P6787

60

5

30

 

 

 

 

 

 

 

 

MP

C5172 C6706 C6707 C6717 C6718 C6719 C6787 C14914 C14981 C15017 C15028 C15043 C15044

P14914 P14981 P15017 P15028 P15043 P15044

120

5

30

 

 

[8]                   Schedule 1, Part 1, entry for Cabergoline in the form Tablet 500 micrograms

substitute:

Cabergoline

Tablet 500 micrograms

Oral

 

Dostinex

PF

MP

C5136 C5137 C5172 C5357 C5398 C14918 C14959 C14983 C15005

P5172

2

0

2

 

 

 

 

 

 

 

 

NP

C5172

 

2

0

2

 

 

 

 

 

 

 

 

MP

C5136 C5137 C5172 C5357 C5398 C14918 C14959 C14983 C15005

P5136 P5137 P5357 P5398

8

5

8

 

 

 

 

 

 

 

 

MP

C5136 C5137 C5172 C5357 C5398 C14918 C14959 C14983 C15005

P14918 P14959 P14983 P15005

16

5

8

 

 

[9]                   Schedule 1, Part 1, entry for Carbamazepine in the form Oral suspension 100 mg per 5 mL, 300 mL

substitute:

Carbamazepine

Oral suspension 100 mg per 5 mL, 300 mL

Oral

 

Tegretol Liquid

NV

PDP

 

 

1

0

1

 

 

 

 

 

 

 

 

MP NP

 

 

1

5

1

 

 

 

 

 

 

 

 

MP NP

 

P14238

2

5

1

 

 

[10]               Schedule 1, Part 1, entry for Carbamazepine in the form Tablet 200 mg (controlled release)

substitute:

 

Tablet 200 mg (controlled release)

Oral

 

Tegretol CR 200

NV

PDP

 

 

200

0

200

 

 

 

 

 

 

 

 

MP NP

 

 

200

2

200

 

 

 

 

 

 

 

 

MP NP

 

P14238

400

2

200

 

 

[11]               Schedule 1, Part 1, entry for Carbamazepine in the form Tablet 400 mg (controlled release)

substitute:

 

Tablet 400 mg (controlled release)

Oral

 

Tegretol CR 400

NV

PDP

 

 

200

0

200

 

 

 

 

 

 

 

 

MP NP

 

 

200

2

200

 

 

 

 

 

 

 

 

MP NP

 

P14238

400

2

200

 

 

[12]               Schedule 1, Part 1, entry for Carbimazole

substitute:

Carbimazole

Tablet 5 mg

Oral

a

Neo-Mercazole

GH

MP NP

 

 

200

2

100

 

 

 

 

 

a

THIRAZOL

NB

MP NP

 

 

200

2

100

 

 

 

 

 

a

WP Carbimazole

TN

MP NP

 

 

200

2

100

 

 

 

 

 

a

Neo-Mercazole

GH

MP NP

 

P14238

400

2

100

 

 

 

 

 

a

THIRAZOL

NB

MP NP

 

P14238

400

2

100

 

 

 

 

 

a

WP Carbimazole

TN

MP NP

 

P14238

400

2

100

 

 

[13]               Schedule 1, Part 1, entry for Ciclosporin in the form Capsule 10 mg

substitute:

Ciclosporin

Capsule 10 mg

Oral

 

Neoral 10

NV

MP

 

 

120

3

60

 

 

 

 

 

 

 

 

MP

 

P6631 P6638 P6643 P6660 P9694 P9695 P9742 P9764 P13122 P13168

120
CN6631 CN6638 CN6643 CN6660 CN9694 CN9695 CN9742 CN9764 CN13122 CN13168

5
CN6631 CN6638 CN6643 CN6660 CN9694 CN9695 CN9742 CN9764 CN13122 CN13168

60

 

C(100)

 

 

 

 

 

 

MP

 

P14238

240

3

60

 

 

[14]               Schedule 1, Part 1, entry for Ciclosporin in the form Capsule 25 mg

substitute:

 

Capsule 25 mg

Oral

a

APO-Ciclosporin

TX

MP

 

 

60

3

30

 

 

 

 

 

a

Cyclosporin Sandoz

SZ

MP

 

 

60

3

30

 

 

 

 

 

a

Neoral 25

NV

MP

 

 

60

3

30

 

 

 

 

 

a

APO-Ciclosporin

TX

MP

 

P14238

120

3

30

 

 

 

 

 

a

Cyclosporin Sandoz

SZ

MP

 

P14238

120

3

30

 

 

 

 

 

a

Neoral 25

NV

MP

 

P14238

120

3

30

 

 

 

 

 

a

APO-Ciclosporin

TX

MP

 

P6631 P6638 P6643 P6660 P9694 P9695 P9742 P9764 P13122 P13168

120
CN6631 CN6638 CN6643 CN6660 CN9694 CN9695 CN9742 CN9764 CN13122 CN13168

5
CN6631 CN6638 CN6643 CN6660 CN9694 CN9695 CN9742 CN9764 CN13122 CN13168

30

 

C(100)

 

 

 

a

Cyclosporin Sandoz

SZ

MP

 

P6631 P6638 P6643 P6660 P9694 P9695 P9742 P9764 P13122 P13168

120
CN6631 CN6638 CN6643 CN6660 CN9694 CN9695 CN9742 CN9764 CN13122 CN13168

5
CN6631 CN6638 CN6643 CN6660 CN9694 CN9695 CN9742 CN9764 CN13122 CN13168

30

 

C(100)

 

 

 

a

Neoral 25

NV

MP

 

P6631 P6638 P6643 P6660 P9694 P9695 P9742 P9764 P13122 P13168

120
CN6631 CN6638 CN6643 CN6660 CN9694 CN9695 CN9742 CN9764 CN13122 CN13168

5
CN6631 CN6638 CN6643 CN6660 CN9694 CN9695 CN9742 CN9764 CN13122 CN13168

30

 

C(100)

[15]               Schedule 1, Part 1, entry for Ciclosporin in the form Capsule 50 mg

substitute:

 

Capsule 50 mg

Oral

a

APO-Ciclosporin

TX

MP

 

 

60

3

30

 

 

 

 

 

a

Cyclosporin Sandoz

SZ

MP

 

 

60

3

30

 

 

 

 

 

a

Neoral 50

NV

MP

 

 

60

3

30

 

 

 

 

 

a

APO-Ciclosporin

TX

MP

 

P14238

120

3

30

 

 

 

 

 

a

Cyclosporin Sandoz

SZ

MP

 

P14238

120

3

30

 

 

 

 

 

a

Neoral 50

NV

MP

 

P14238

120

3

30

 

 

 

 

 

a

APO-Ciclosporin

TX

MP

 

P6631 P6638 P6643 P6660 P9694 P9695 P9742 P9764 P13122 P13168

120
CN6631 CN6638 CN6643 CN6660 CN9694 CN9695 CN9742 CN9764 CN13122 CN13168

5
CN6631 CN6638 CN6643 CN6660 CN9694 CN9695 CN9742 CN9764 CN13122 CN13168

30

 

C(100)

 

 

 

a

Cyclosporin Sandoz

SZ

MP

 

P6631 P6638 P6643 P6660 P9694 P9695 P9742 P9764 P13122 P13168

120
CN6631 CN6638 CN6643 CN6660 CN9694 CN9695 CN9742 CN9764 CN13122 CN13168

5
CN6631 CN6638 CN6643 CN6660 CN9694 CN9695 CN9742 CN9764 CN13122 CN13168

30

 

C(100)

 

 

 

a

Neoral 50

NV

MP

 

P6631 P6638 P6643 P6660 P9694 P9695 P9742 P9764 P13122 P13168

120
CN6631 CN6638 CN6643 CN6660 CN9694 CN9695 CN9742 CN9764 CN13122 CN13168

5
CN6631 CN6638 CN6643 CN6660 CN9694 CN9695 CN9742 CN9764 CN13122 CN13168

30

 

C(100)

[16]               Schedule 1, Part 1, entry for Ciclosporin in the form Capsule 100 mg

substitute:

 

Capsule 100 mg

Oral

a

APO-Ciclosporin

TX

MP

 

 

60

3

30

 

 

 

 

 

a

Cyclosporin Sandoz

SZ

MP

 

 

60

3

30

 

 

 

 

 

a

Neoral 100

NV

MP

 

 

60

3

30

 

 

 

 

 

a

APO-Ciclosporin

TX

MP

 

P14238

120

3

30

 

 

 

 

 

a

Cyclosporin Sandoz

SZ

MP

 

P14238

120

3

30

 

 

 

 

 

a

Neoral 100

NV

MP

 

P14238

120

3

30

 

 

 

 

 

a

APO-Ciclosporin

TX

MP

 

P6631 P6638 P6643 P6660 P9694 P9695 P9742 P9764 P13122 P13168

120
CN6631 CN6638 CN6643 CN6660 CN9694 CN9695 CN9742 CN9764 CN13122 CN13168

5
CN6631 CN6638 CN6643 CN6660 CN9694 CN9695 CN9742 CN9764 CN13122 CN13168

30

 

C(100)

 

 

 

a

Cyclosporin Sandoz

SZ

MP

 

P6631 P6638 P6643 P6660 P9694 P9695 P9742 P9764 P13122 P13168

120
CN6631 CN6638 CN6643 CN6660 CN9694 CN9695 CN9742 CN9764 CN13122 CN13168

5
CN6631 CN6638 CN6643 CN6660 CN9694 CN9695 CN9742 CN9764 CN13122 CN13168

30

 

C(100)

 

 

 

a

Neoral 100

NV

MP

 

P6631 P6638 P6643 P6660 P9694 P9695 P9742 P9764 P13122 P13168

120
CN6631 CN6638 CN6643 CN6660 CN9694 CN9695 CN9742 CN9764 CN13122 CN13168

5
CN6631 CN6638 CN6643 CN6660 CN9694 CN9695 CN9742 CN9764 CN13122 CN13168

30

 

C(100)

[17]               Schedule 1, Part 1, entry for Ciclosporin in the form Oral liquid 100 mg per mL, 50 mL

substitute:

 

Oral liquid 100 mg per mL, 50 mL

Oral

 

Neoral

NV

MP

 

 

2

3

1

 

 

 

 

 

 

 

 

MP

 

P14238

4

3

1

 

 

 

 

 

 

 

 

MP

 

P6631 P6638 P6643 P6660 P9694 P9695 P9742 P9764 P13122 P13168

4
CN6631 CN6638 CN6643 CN6660 CN9694 CN9695 CN9742 CN9764 CN13122 CN13168

5
CN6631 CN6638 CN6643 CN6660 CN9694 CN9695 CN9742 CN9764 CN13122 CN13168

1

 

C(100)

[18]               Schedule 1, Part 1, entry for Cortisone

substitute:

Cortisone

Tablet containing cortisone acetate 5 mg

Oral

 

Cortate

AS

MP NP

 

 

50

4

50

 

 

 

 

 

 

 

 

MP NP

 

P14238

100

4

50

 

 

 

Tablet containing cortisone acetate 25 mg

Oral

 

Cortate

AS

MP NP

 

 

60

4

60

 

 

 

 

 

 

 

 

MP NP

 

P14238

120

4

60

 

 

[19]               Schedule 1, Part 1, entry for Cyproterone

substitute:

Cyproterone

Tablet containing cyproterone acetate 50 mg

Oral

a

ANTERONE 50

RW

MP

 

P5532

20
CN5532

5
CN5532

20

 

 

 

 

 

a

Cyproterone Sandoz

HX

MP

 

P5532

20
CN5532

5
CN5532

20

 

 

 

 

 

a

Pharmacor Cyproterone 50

CR

MP

 

P5532

20
CN5532

5
CN5532

20

 

 

 

 

 

a

ANTERONE 50

RW

MP

 

P14868

40
CN14868

5
CN14868

20

 

 

 

 

 

a

Cyproterone Sandoz

HX

MP

 

P14868

40
CN14868

5
CN14868

20

 

 

 

 

 

a

Pharmacor Cyproterone 50

CR

MP

 

P14868

40
CN14868

5
CN14868

20

 

 

 

 

 

a

Androcur

BN

MP

 

 

100

5

50

 

 

 

 

 

a

ANTERONE 50

RW

MP

 

 

100

5

50

 

 

 

 

 

a

Cyproterone Sandoz

HX

MP

 

 

100

5

50

 

 

 

 

 

a

Pharmacor Cyproterone 50

CR

MP

 

 

100

5

50

 

 

 

 

 

a

Androcur

BN

MP

 

P14238

200

5

50

 

 

 

 

 

a

ANTERONE 50

RW

MP

 

P14238

200

5

50

 

 

 

 

 

a

Cyproterone Sandoz

HX

MP

 

P14238

200

5

50

 

 

 

 

 

a

Pharmacor Cyproterone 50

CR

MP

 

P14238

200

5

50

 

 

 

Tablet containing cyproterone acetate 100 mg

Oral

a

Androcur-100

BN

MP

 

 

50

5

50

 

 

 

 

 

a

ANTERONE 100

RW

MP

 

 

50

5

50

 

 

 

 

 

a

Cyproterone Sandoz

HX

MP

 

 

50

5

50

 

 

 

 

 

a

Pharmacor Cyproterone 100

CR

MP

 

 

50

5

50

 

 

 

 

 

a

Androcur-100

BN

MP

 

P14238

100

5

50

 

 

 

 

 

a

ANTERONE 100

RW

MP

 

P14238

100

5

50

 

 

 

 

 

a

Cyproterone Sandoz

HX

MP

 

P14238

100

5

50

 

 

 

 

 

a

Pharmacor Cyproterone 100

CR

MP

 

P14238

100

5

50

 

 

[20]               Schedule 1, Part 1, entry for Dapagliflozin

substitute:

Dapagliflozin

Tablet 10 mg (as propanediol monohydrate)

Oral

 

Forxiga

AP

MP

C4991 C5629 C7495 C7506 C7528 C12477 C13230 C14859 C14905 C14949 C14974 C14976

P4991 P5629 P7495 P7506 P7528 P12477 P13230

28

5

28

 

 

 

 

 

 

 

 

NP

C4991 C5629 C7495 C7506 C12477 C13230 C14859 C14905 C14949 C14974 C14976

P4991 P5629 P7495 P7506 P12477 P13230

28

5

28

 

 

 

 

 

 

 

 

MP

C4991 C5629 C7495 C7506 C7528 C12477 C13230 C14859 C14905 C14949 C14974 C14976

P14859 P14905 P14949 P14974 P14976

56

5

28

 

 

 

 

 

 

 

 

NP

C4991 C5629 C7495 C7506 C12477 C13230 C14859 C14905 C14949 C14974 C14976

P14859 P14905 P14949 P14974 P14976

56

5

28

 

 

[21]               Schedule 1, Part 1, entry for Dapagliflozin with metformin

substitute:

Dapagliflozin with metformin

Tablet (modified release) containing 5 mg dapagliflozin (as propanediol monohydrate) with 1000 mg metformin hydrochloride

Oral

 

Xigduo XR 5/1000

AP

MP

C5631 C5657 C5739 C5798 C7492 C7498 C14878 C14881 C14924 C14987

P5631 P5657 P5739 P5798 P7492 P7498

56

5

56

 

 

 

 

 

 

 

 

NP

C5631 C5657 C5739 C5798 C7492 C14878 C14881 C14924 C14987

P5631 P5657 P5739 P5798 P7492

56

5

56

 

 

 

 

 

 

 

 

MP

C5631 C5657 C5739 C5798 C7492 C7498 C14878 C14881 C14924 C14987

P14878 P14881 P14924 P14987

112

5

56

 

 

 

 

 

 

 

 

NP

C5631 C5657 C5739 C5798 C7492 C14878 C14881 C14924 C14987

P14878 P14881 P14924 P14987

112

5

56

 

 

 

Tablet (modified release) containing 10 mg dapagliflozin (as propanediol monohydrate) with 500 mg metformin hydrochloride

Oral

 

Xigduo XR 10/500

AP

MP

C5631 C5657 C5739 C5798 C7492 C7498 C14878 C14881 C14924 C14987

P5631 P5657 P5739 P5798 P7492 P7498

28

5

28

 

 

 

 

 

 

 

 

NP

C5631 C5657 C5739 C5798 C7492 C14878 C14881 C14924 C14987

P5631 P5657 P5739 P5798 P7492

28

5

28

 

 

 

 

 

 

 

 

MP

C5631 C5657 C5739 C5798 C7492 C7498 C14878 C14881 C14924 C14987

P14878 P14881 P14924 P14987

56

5

28

 

 

 

 

 

 

 

 

NP

C5631 C5657 C5739 C5798 C7492 C14878 C14881 C14924 C14987

P14878 P14881 P14924 P14987

56

5

28

 

 

 

Tablet (modified release) containing 10 mg dapagliflozin (as propanediol monohydrate) with 1000 mg metformin hydrochloride

Oral

 

Xigduo XR 10/1000

AP

MP

C5631 C5657 C5739 C5798 C7492 C7498 C14878 C14881 C14924 C14987

P5631 P5657 P5739 P5798 P7492 P7498

28

5

28

 

 

 

 

 

 

 

 

NP

C5631 C5657 C5739 C5798 C7492 C14878 C14881 C14924 C14987

P5631 P5657 P5739 P5798 P7492

28

5

28

 

 

 

 

 

 

 

 

MP

C5631 C5657 C5739 C5798 C7492 C7498 C14878 C14881 C14924 C14987

P14878 P14881 P14924 P14987

56

5

28

 

 

 

 

 

 

 

 

NP

C5631 C5657 C5739 C5798 C7492 C14878 C14881 C14924 C14987

P14878 P14881 P14924 P14987

56

5

28

 

 

[22]               Schedule 1, Part 1, entry for Desmopressin in the form Tablet containing desmopressin acetate 200 micrograms

substitute:

 

Tablet containing desmopressin acetate 200 micrograms

Oral

 

Minirin

FP

MP

C5266 C5295 C5413 C14842 C14972 C15012

P5295 P5413

30

5

30

 

 

 

 

 

 

 

 

NP

C5295 C5413 C14842 C14972

P5295 P5413

30

5

30

 

 

 

 

 

 

 

 

MP

C5266 C5295 C5413 C14842 C14972 C15012

P14842 P14972

60

5

30

 

 

 

 

 

 

 

 

NP

C5295 C5413 C14842 C14972

P14842 P14972

60

5

30

 

 

 

 

 

 

 

 

MP

C5266 C5295 C5413 C14842 C14972 C15012

P5266

90

5

30

 

 

 

 

 

 

 

 

MP

C5266 C5295 C5413 C14842 C14972 C15012

P15012

180

5

30

 

 

[23]               Schedule 1, Part 1, entry for Desmopressin in the form Wafer 120 micrograms (as acetate)

substitute:

 

Wafer 120 micrograms (as acetate)

Sublingual

 

Minirin Melt

FP

MP NP

C5226 C5412 C14842 C14972

P5226 P5412

30

5

30

 

 

 

 

 

 

 

 

MP NP

C5226 C5412 C14842 C14972

P14842 P14972

60

5

30

 

 

[24]               Schedule 1, Part 1, entry for Desmopressin in the form Wafer 240 micrograms (as acetate)

substitute:


 

Wafer 240 micrograms (as acetate)

Sublingual

 

Minirin Melt

FP

MP NP

C5226 C5412 C14945 C15025

P5226 P5412

30

5

30

 

 

 

 

 

 

 

 

MP NP

C5226 C5412 C14945 C15025

P14945 P15025

60

5

30

 

 

[25]               Schedule 1, Part 1, entry for Dexamethasone in the form Tablet 500 micrograms

substitute:

 

Tablet 500 micrograms

Oral

 

Dexmethsone

AS

MP NP

 

 

30

4

30

 

 

 

 

 

 

 

 

MP NP

 

P14238

60

4

30

 

 

[26]               Schedule 1, Part 1, entry for Dutasteride

substitute:

Dutasteride

Capsule 500 micrograms

Oral

a

APO-Dutasteride

TX

MP NP

C6202 C15018

P6202

30

5

30

 

 

 

 

 

a

Avodart

GK

MP NP

C6202 C15018

P6202

30

5

30

 

 

 

 

 

a

APO-Dutasteride

TX

MP NP

C6202 C15018

P15018

60

5

30

 

 

 

 

 

a

Avodart

GK

MP NP

C6202 C15018

P15018

60

5

30

 

 

[27]               Schedule 1, Part 1, entry for Dutasteride with tamsulosin

substitute:

Dutasteride with tamsulosin

Capsule containing dutasteride 500 micrograms with tamsulosin hydrochloride 400 micrograms

Oral

a

Doubluts

GC

MP NP

C6189 C15004

P6189

30

5

30

 

 

 

 

 

a

Duodart 500ug/400ug

GK

MP NP

C6189 C15004

P6189

30

5

30

 

 

 

 

 

a

Doubluts

GC

MP NP

C6189 C15004

P15004

60

5

30

 

 

 

 

 

a

Duodart 500ug/400ug

GK

MP NP

C6189 C15004

P15004

60

5

30

 

 

[28]               Schedule 1, Part 1, entry for Empagliflozin

substitute:

Empagliflozin

Tablet 10 mg

Oral

 

Jardiance

BY

MP

C4991 C5629 C7495 C7506 C7528 C12477 C14471 C14859 C14905 C14949 C14974 C14976

P4991 P5629 P7495 P7506 P7528 P12477 P14471

30

5

30

 

 

 

 

 

 

 

 

NP

C4991 C5629 C7495 C7506 C12477 C14471 C14859 C14905 C14949 C14974 C14976

P4991 P5629 P7495 P7506 P12477 P14471

30

5

30

 

 

 

 

 

 

 

 

MP

C4991 C5629 C7495 C7506 C7528 C12477 C14471 C14859 C14905 C14949 C14974 C14976

P14859 P14905 P14949 P14974 P14976

60

5

30

 

 

 

 

 

 

 

 

NP

C4991 C5629 C7495 C7506 C12477 C14471 C14859 C14905 C14949 C14974 C14976

P14859 P14905 P14949 P14974 P14976

60

5

30

 

 

 

Tablet 25 mg

Oral

 

Jardiance

BY

MP

C4991 C5629 C7495 C7506 C7528 C14859 C14905 C14949 C14974

P4991 P5629 P7495 P7506 P7528

30

5

30

 

 

 

 

 

 

 

 

NP

C4991 C5629 C7495 C7506 C14859 C14905 C14949 C14974

P4991 P5629 P7495 P7506

30

5

30

 

 

 

 

 

 

 

 

MP

C4991 C5629 C7495 C7506 C7528 C14859 C14905 C14949 C14974

P14859 P14905 P14949 P14974

60

5

30

 

 

 

 

 

 

 

 

NP

C4991 C5629 C7495 C7506 C14859 C14905 C14949 C14974

P14859 P14905 P14949 P14974

60

5

30

 

 

[29]               Schedule 1, Part 1, entry for Empagliflozin with linagliptin

substitute:

Empagliflozin with linagliptin

Tablet containing 10 mg empagliflozin with 5 mg linagliptin

Oral

 

Glyxambi

BY

MP

C7524 C7556 C14885

P7524 P7556

30

5

30

 

 

 

 

 

 

 

 

NP

C7556 C14885

P7556

30

5

30

 

 

 

 

 

 

 

 

MP

C7524 C7556 C14885

P14885

60

5

30

 

 

 

 

 

 

 

 

NP

C7556 C14885

P14885

60

5

30

 

 

 

Tablet containing 25 mg empagliflozin with 5 mg linagliptin

Oral

 

Glyxambi

BY

MP

C7524 C7556 C14885

P7524 P7556

30

5

30

 

 

 

 

 

 

 

 

NP

C7556 C14885

P7556

30

5

30

 

 

 

 

 

 

 

 

MP

C7524 C7556 C14885

P14885

60

5

30

 

 

 

 

 

 

 

 

NP

C7556 C14885

P14885

60

5

30

 

 

[30]               Schedule 1, Part 1, entry for Empagliflozin with metformin

substitute:

Empagliflozin with metformin

Tablet containing 5 mg empagliflozin with 1 g metformin hydrochloride

Oral

 

Jardiamet 5 mg/1000 mg

BY

MP

C5657 C5798 C5953 C5966 C7492 C7498 C14878 C14881 C14924 C14925

P5657 P5798 P5953 P5966 P7492 P7498

60

5

60

 

 

 

 

 

 

 

 

NP

C5657 C5798 C5966 C7492 C14878 C14881 C14924 C14925

P5657 P5798 P5966 P7492

60

5

60

 

 

 

 

 

 

 

 

MP

C5657 C5798 C5953 C5966 C7492 C7498 C14878 C14881 C14924 C14925

P14878 P14881 P14924 P14925

120

5

60

 

 

 

 

 

 

 

 

NP

C5657 C5798 C5966 C7492 C14878 C14881 C14924 C14925

P14878 P14881 P14924 P14925

120

5

60

 

 

 

Tablet containing 5 mg empagliflozin with 500 mg metformin hydrochloride

Oral

 

Jardiamet 5 mg/500 mg

BY

MP

C5657 C5798 C5953 C5966 C7492 C7498 C14878 C14881 C14924 C14925

P5657 P5798 P5953 P5966 P7492 P7498

60

5

60

 

 

 

 

 

 

 

 

NP

C5657 C5798 C5966 C7492 C14878 C14881 C14924 C14925

P5657 P5798 P5966 P7492

60

5

60

 

 

 

 

 

 

 

 

MP

C5657 C5798 C5953 C5966 C7492 C7498 C14878 C14881 C14924 C14925

P14878 P14881 P14924 P14925

120

5

60

 

 

 

 

 

 

 

 

NP

C5657 C5798 C5966 C7492 C14878 C14881 C14924 C14925

P14878 P14881 P14924 P14925

120

5

60

 

 

 

Tablet containing 12.5 mg empagliflozin with 1 g metformin hydrochloride

Oral

 

Jardiamet 12.5 mg/1000 mg

BY

MP

C5657 C5798 C5953 C5966 C7492 C7498 C14878 C14881 C14924 C14925

P5657 P5798 P5953 P5966 P7492 P7498

60

5

60

 

 

 

 

 

 

 

 

NP

C5657 C5798 C5966 C7492 C14878 C14881 C14924 C14925

P5657 P5798 P5966 P7492

60

5

60

 

 

 

 

 

 

 

 

MP

C5657 C5798 C5953 C5966 C7492 C7498 C14878 C14881 C14924 C14925

P14878 P14881 P14924 P14925

120

5

60

 

 

 

 

 

 

 

 

NP

C5657 C5798 C5966 C7492 C14878 C14881 C14924 C14925

P14878 P14881 P14924 P14925

120

5

60

 

 

 

Tablet containing 12.5 mg empagliflozin with 500 mg metformin hydrochloride

Oral

 

Jardiamet 12.5 mg/500 mg

BY

MP

C5657 C5798 C5953 C5966 C7492 C7498 C14878 C14881 C14924 C14925

P5657 P5798 P5953 P5966 P7492 P7498

60

5

60

 

 

 

 

 

 

 

 

NP

C5657 C5798 C5966 C7492 C14878 C14881 C14924 C14925

P5657 P5798 P5966 P7492

60

5

60

 

 

 

 

 

 

 

 

MP

C5657 C5798 C5953 C5966 C7492 C7498 C14878 C14881 C14924 C14925

P14878 P14881 P14924 P14925

120

5

60

 

 

 

 

 

 

 

 

NP

C5657 C5798 C5966 C7492 C14878 C14881 C14924 C14925

P14878 P14881 P14924 P14925

120

5

60

 

 

[31]               Schedule 1, Part 1, entry for Eprosartan

substitute:


Eprosartan

Tablet 600 mg (as mesilate)

Oral

 

Teveten

GO

MP NP

 

 

28

5

28

 

 

 

 

 

 

 

 

MP NP

 

P6328 P6329 P6332 P6351

28
CN6328 CN6329 CN6332 CN6351

5
CN6328 CN6329 CN6332 CN6351

28

 

 

 

 

 

 

 

 

MP NP

 

P14238

56

5

28

 

 

 

 

 

 

 

 

MP NP

 

P14841 P14969 P14970 P15009

56
CN14841 CN14969 CN14970 CN15009

5
CN14841 CN14969 CN14970 CN15009

28

 

 

[32]               Schedule 1, Part 1, entry for Estradiol in the form Transdermal gel 1 mg (as hemihydrate) in 1 g sachet, 28

substitute:

 

Transdermal gel 1 mg (as hemihydrate) in 1 g sachet, 28

Transdermal

 

Sandrena

OX

MP NP

 

 

1

5

1

 

 

 

 

 

 

 

 

MP NP

 

P14238

2

5

1

 

 

[33]               Schedule 1, Part 1, entry for Estradiol in the form Pessary (modified release) 10 micrograms (as hemihydrate)

substitute:

 

Pessary (modified release) 10 micrograms (as hemihydrate)

Vaginal

a

Estro-Pess

AS

MP NP

 

 

18

2

18

 

 

 

 

 

a

Vagifem Low

NO

MP NP

 

 

18

2

18

 

 

 

 

 

a

Estro-Pess

AS

MP NP

 

P14238

36

2

18

 

 

 

 

 

a

Vagifem Low

NO

MP NP

 

P14238

36

2

18

 

 

[34]               Schedule 1, Part 1, entry for Estradiol in the form Tablet containing estradiol valerate 1 mg

substitute:


 

Tablet containing estradiol valerate 1 mg

Oral

 

Progynova

BN

MP NP

 

 

56

2

56

 

 

 

 

 

 

 

 

MP NP

 

P14238

112

2

56

 

 

[35]               Schedule 1, Part 1, entry for Estradiol in the form Tablet 2 mg

substitute:

 

Tablet 2 mg

Oral

 

Zumenon

GO

MP NP

 

 

56

2

56

 

 

 

 

 

 

 

 

MP NP

 

P14238

112

2

56

 

 

[36]               Schedule 1, Part 1, entry for Estradiol in the form Tablet containing estradiol valerate 2 mg

substitute:

 

Tablet containing estradiol valerate 2 mg

Oral

 

Progynova

BN

MP NP

 

 

56

2

56

 

 

 

 

 

 

 

 

MP NP

 

P14238

112

2

56

 

 

[37]               Schedule 1, Part 1, entry for Estradiol and estradiol with dydrogesterone

substitute:

Estradiol and estradiol with dydrogesterone

Pack containing 14 tablets estradiol 1 mg and 14 tablets estradiol 1 mg with dydrogesterone 10 mg

Oral

 

Femoston 1/10

GO

MP NP

 

 

1

5

1

 

 

 

 

 

 

 

 

MP NP

 

P14238

2

5

1

 

 

 

Pack containing 14 tablets estradiol 2 mg and 14 tablets estradiol 2 mg with dydrogesterone 10 mg

Oral

 

Femoston 2/10

GO

MP NP

 

 

1

5

1

 

 

 

 

 

 

 

 

MP NP

 

P14238

2

5

1

 

 

[38]               Schedule 1, Part 1, entry for Estradiol and estradiol with norethisterone

substitute:

Estradiol and estradiol with norethisterone

Pack containing 4 transdermal patches 780 micrograms estradiol (as hemihydrate) and 4 transdermal patches 510 micrograms estradiol (as hemihydrate) with 4.8 mg norethisterone acetate

Transdermal

 

Estalis sequi 50/250

SZ

MP NP

 

 

1

5

1

 

 

 

 

 

 

 

 

MP NP

 

P14238

2

5

1

 

 

 

Pack containing 4 transdermal patches 780 micrograms estradiol (as hemihydrate) and 4 transdermal patches 620 micrograms estradiol (as hemihydrate) with 2.7 mg norethisterone acetate

Transdermal

 

Estalis sequi 50/140

SZ

MP NP

 

 

1

5

1

 

 

 

 

 

 

 

 

MP NP

 

P14238

2

5

1

 

 

[39]               Schedule 1, Part 1, entry for Estradiol with norethisterone in the form Transdermal patches containing 620 micrograms estradiol (as hemihydrate) with 2.7 mg norethisterone acetate, 8

substitute:

 

Transdermal patches containing 620 micrograms estradiol (as hemihydrate) with 2.7 mg norethisterone acetate, 8

Transdermal

 

Estalis continuous 50/140

SZ

MP NP

 

 

1

5

1

 

 

 

 

 

 

 

 

MP NP

 

P14238

2

5

1

 

 

[40]               Schedule 1, Part 1, entry for Estriol

substitute:

Estriol

Vaginal cream 1 mg per g, 15 g

Application

 

Ovestin

AS

MP NP

 

 

1

1

1

 

 

 

 

 

 

 

 

MP NP

 

P14238

2

1

1

 

 

 

Pessaries 500 micrograms, 15

Vaginal

 

Ovestin Ovula

AS

MP NP

 

 

1

2

1

 

 

 

 

 

 

 

 

MP NP

 

P14238

2

2

1

 

 

[41]               Schedule 1, Part 1, entry for Ethosuximide in the form Oral solution 250 mg per 5 mL, 200 mL

substitute:

 

Oral solution 250 mg per 5 mL, 200 mL

Oral

 

Zarontin

IX

MP NP

 

 

1

5

1

 

 

 

 

 

 

 

 

MP NP

 

P14238

2

5

1

 

 

[42]               Schedule 1, Part 1, entry for Everolimus in the form Tablet 0.75 mg

substitute:

 

Tablet 0.75 mg

Oral

a

Certican

NV

MP

 

 

120

3

60

 

 

 

 

 

a

Everocan

CR

MP

 

 

120

3

60

 

 

 

 

 

a

Certican

NV

MP

 

P14238

240

3

60

 

 

 

 

 

a

Everocan

CR

MP

 

P14238

240

3

60

 

 

 

 

 

a

Certican

NV

MP

 

P5554 P5795 P9691 P9693

240
CN5554 CN5795 CN9691 CN9693

5
CN5554 CN5795 CN9691 CN9693

60

 

C(100)

 

 

 

a

Everocan

CR

MP

 

P5554 P5795 P9691 P9693

240
CN5554 CN5795 CN9691 CN9693

5
CN5554 CN5795 CN9691 CN9693

60

 

C(100)

[43]               Schedule 1, Part 1, entry for Everolimus in the form Tablet 1 mg

substitute:

 

Tablet 1 mg

Oral

a

Certican

NV

MP

 

 

120

3

60

 

 

 

 

 

a

Everocan

CR

MP

 

 

120

3

60

 

 

 

 

 

a

Certican

NV

MP

 

P14238

240

3

60

 

 

 

 

 

a

Everocan

CR

MP

 

P14238

240

3

60

 

 

 

 

 

a

Certican

NV

MP

 

P5554 P5795 P9691 P9693

240
CN5554 CN5795 CN9691 CN9693

5
CN5554 CN5795 CN9691 CN9693

60

 

C(100)

 

 

 

a

Everocan

CR

MP

 

P5554 P5795 P9691 P9693

240
CN5554 CN5795 CN9691 CN9693

5
CN5554 CN5795 CN9691 CN9693

60

 

C(100)

[44]               Schedule 1, Part 1, entry for Exemestane

substitute:

Exemestane

Tablet 25 mg

Oral

a

APO-Exemestane

TX

MP

C4796 C5522 C14992 C15031

P4796 P5522

30

5

30

 

 

 

 

 

 

 

 

NP

C5522 C14992

P5522

30

5

30

 

 

 

 

 

a

Aromasin

PF

MP

C4796 C5522 C14992 C15031

P4796 P5522

30

5

30

 

 

 

 

 

 

 

 

NP

C5522 C14992

P5522

30

5

30

 

 

 

 

 

a

Exemestane GH

GQ

MP

C4796 C5522 C14992 C15031

P4796 P5522

30

5

30

 

 

 

 

 

 

 

 

NP

C5522 C14992

P5522

30

5

30

 

 

 

 

 

a

Exemestane Sandoz

SZ

MP

C4796 C5522 C14992 C15031

P4796 P5522

30

5

30

 

 

 

 

 

 

 

 

NP

C5522 C14992

P5522

30

5

30

 

 

 

 

 

a

APO-Exemestane

TX

MP

C4796 C5522 C14992 C15031

P14992 P15031

60

5

30

 

 

 

 

 

 

 

 

NP

C5522 C14992

P14992

60

5

30

 

 

 

 

 

a

Aromasin

PF

MP

C4796 C5522 C14992 C15031

P14992 P15031

60

5

30

 

 

 

 

 

 

 

 

NP

C5522 C14992

P14992

60

5

30

 

 

 

 

 

a

Exemestane GH

GQ

MP

C4796 C5522 C14992 C15031

P14992 P15031

60

5

30

 

 

 

 

 

 

 

 

NP

C5522 C14992

P14992

60

5

30

 

 

 

 

 

a

Exemestane Sandoz

SZ

MP

C4796 C5522 C14992 C15031

P14992 P15031

60

5

30

 

 

 

 

 

 

 

 

NP

C5522 C14992

P14992

60

5

30

 

 

[45]               Schedule 1, Part 1, entry for Glibenclamide

substitute:

Glibenclamide

Tablet 5 mg

Oral

 

Daonil

SW

MP NP

 

 

100

5

100

 

 

 

 

 

 

 

 

MP NP

 

P14238

200

5

100

 

 

[46]               Schedule 1, Part 1, entry for Gliclazide in the form Tablet 60 mg (modified release)

substitute:

 

Tablet 60 mg (modified release)

Oral

a

ARDIX GLICLAZIDE 60mg MR

XT

MP NP

 

 

60

5

60

 

 

 

 

 

a

Diamicron 60mg MR

SE

MP NP

 

 

60

5

60

 

 

 

 

 

a

Gliclazide Lupin MR

GQ

MP NP

 

 

60

5

60

 

 

 

 

 

a

Pharmacor Gliclazide MR

CR

MP NP

 

 

60

5

60

 

 

 

 

 

a

ARDIX GLICLAZIDE 60mg MR

XT

MP NP

 

P14238

120

5

60

 

 

 

 

 

a

Diamicron 60mg MR

SE

MP NP

 

P14238

120

5

60

 

 

 

 

 

a

Gliclazide Lupin MR

GQ

MP NP

 

P14238

120

5

60

 

 

 

 

 

a

Pharmacor Gliclazide MR

CR

MP NP

 

P14238

120

5

60

 

 

[47]               Schedule 1, Part 1, entry for Gliclazide in the form Tablet 80 mg (modified release)

substitute:

 

Tablet 80 mg

Oral

a

APO-Gliclazide

TX

MP NP

 

 

100

5

100

 

 

 

 

 

a

APX-Gliclazide

TY

MP NP

 

 

100

5

100

 

 

 

 

 

a

Glyade

AF

MP NP

 

 

100

5

100

 

 

 

 

 

a

Nidem

RW

MP NP

 

 

100

5

100

 

 

 

 

 

a

APO-Gliclazide

TX

MP NP

 

P14238

200

5

100

 

 

 

 

 

a

APX-Gliclazide

TY

MP NP

 

P14238

200

5

100

 

 

 

 

 

a

Glyade

AF

MP NP

 

P14238

200

5

100

 

 

 

 

 

a

Nidem

RW

MP NP

 

P14238

200

5

100

 

 

[48]               Schedule 1, Part 1, entry for Glimepiride

substitute:

Glimepiride

Tablet 1 mg

Oral

a

Amaryl

SW

MP NP

 

 

30

5

30

 

 

 

 

 

a

Aylide 1

AF

MP NP

 

 

30

5

30

 

 

 

 

 

a

Glimepiride APOTEX

GX

MP NP

 

 

30

5

30

 

 

 

 

 

a

Glimepiride Sandoz

SZ

MP NP

 

 

30

5

30

 

 

 

 

 

a

Amaryl

SW

MP NP

 

P14238

60

5

30

 

 

 

 

 

a

Aylide 1

AF

MP NP

 

P14238

60

5

30

 

 

 

 

 

a

Glimepiride APOTEX

GX

MP NP

 

P14238

60

5

30

 

 

 

 

 

a

Glimepiride Sandoz

SZ

MP NP

 

P14238

60

5

30

 

 

 

Tablet 2 mg

Oral

a

Aylide 2

AF

MP NP

 

 

30

5

30

 

 

 

 

 

a

Glimepiride APOTEX

GX

MP NP

 

 

30

5

30

 

 

 

 

 

a

Glimepiride Sandoz

SZ

MP NP

 

 

30

5

30

 

 

 

 

 

a

Aylide 2

AF

MP NP

 

P14238

60

5

30

 

 

 

 

 

a

Glimepiride APOTEX

GX

MP NP

 

P14238

60

5

30

 

 

 

 

 

a

Glimepiride Sandoz

SZ

MP NP

 

P14238

60

5

30

 

 

 

Tablet 3 mg

Oral

a

Aylide 3

AF

MP NP

 

 

30

5

30

 

 

 

 

 

a

Glimepiride APOTEX

GX

MP NP

 

 

30

5

30

 

 

 

 

 

a

Glimepiride Sandoz

SZ

MP NP

 

 

30

5

30

 

 

 

 

 

a

Aylide 3